Clinical significance of Tmax [Regulatives / Guidelines]

posted by M.tareq  – 2017-10-12 09:53 (2828 d 09:42 ago) – Posting: # 17890
Views: 6,508

Dear all ,

I have a question about Tmax from clinical perspective.

According to EMA guidance:
"A statistical evaluation of tmax is not required. However, if rapid release is claimed to be clinically relevant and of importance for onset of action or is related to adverse events, there should be no apparent difference in median tmax and its variability between test and reference product."

If a fast disintegrating tab has a tmax earlier than the conventional release, does it prove that it has an earlier onset of action?

Thanks in advance and Best regards

Complete thread:

UA Flag
Activity
 Admin contact
23,429 posts in 4,930 threads, 1,679 registered users;
42 visitors (2 registered, 40 guests [including 7 identified bots]).
Forum time: 19:35 CEST (Europe/Vienna)

To know that we know what we know,
and to know that we do not know what we do not know,
that is true knowledge.    Nicolaus Copernicus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5